https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51358 Wed 28 Feb 2024 16:08:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47693 Wed 25 Jan 2023 08:42:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54893 Wed 20 Mar 2024 13:33:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51025 Wed 16 Aug 2023 10:02:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41663 Wed 13 Mar 2024 18:26:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15020 Wed 11 Apr 2018 16:06:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28678 Wed 11 Apr 2018 15:54:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7653 Wed 11 Apr 2018 15:25:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29475 Wed 11 Apr 2018 15:08:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19681 Wed 11 Apr 2018 14:42:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17447 Wed 11 Apr 2018 10:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27693 Wed 11 Apr 2018 10:30:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5340 Wed 11 Apr 2018 10:24:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15136 Wed 11 Apr 2018 09:13:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48776 Wed 05 Apr 2023 14:02:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48997 35 cigarettes/day. Lung cancer risk was lower with quitting at any age but remained higher than never-smokers for quitters aged >25y. By age 80y, an estimated 48.3% of current-smokers (41.1% never-smokers) will develop cancer, and 14% will develop lung cancer, including 7.7% currently smoking 1-5 cigarettes/day and 26.4% for >35 cigarettes/day (1.0% never-smokers). Cancer risk for Australian smokers is significant, even for 'light' smokers. These contemporary estimates underpin the need for continued investment in strategies to prevent smoking uptake and facilitate cessation, which remain key to reducing cancer morbidity and mortality worldwide.]]> Wed 03 May 2023 12:03:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50708 Wed 02 Aug 2023 15:00:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36667 2 standard alcoholic drinks/day (41.2%). In conclusion, large fractions of kidney and bladder cancers in Australia are preventable by behavior change.]]> Tue 26 Jul 2022 11:43:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37400 n = 214,536) to national cancer and death registries, and estimated the strength of the associations between behaviours causally related to cancer incidence and death using adjusted proportional hazards models. We estimated exposure prevalence from representative health surveys. We combined these estimates to calculate Population Attributable Fractions (PAFs) with 95% confidence intervals (CIs), and compared PAFs for population subgroups. During the first 10 years follow‐up, there were 640 incident breast cancers for premenopausal women, 2,632 for postmenopausal women, and 8,761 deaths from any cause. Of future breast cancers for premenopausal women, any regular alcohol consumption explains 12.6% (CI = 4.3–20.2%), current use of oral contraceptives for ≥5 years 7.1% (CI = 0.3–13.5%), and these factors combined 18.8% (CI = 9.1–27.4%). Of future breast cancers for postmenopausal women, overweight or obesity (BMI ≥25 kg/m2) explains 12.8% (CI = 7.8–17.5%), current use of menopausal hormone therapy (MHT) 6.9% (CI = 4.8–8.9%), any regular alcohol consumption 6.6% (CI = 1.5–11.4%), and these factors combined 24.2% (CI = 17.6–30.3%). The MHT‐related postmenopausal breast cancer burden varied by body fatness, alcohol consumption and socio‐economic status, the body fatness‐related postmenopausal breast cancer burden by alcohol consumption and educational attainment, and the alcohol‐related postmenopausal breast cancer burden by breast feeding history. Our results provide evidence to support targeted and population‐level cancer control activities.]]> Tue 25 Oct 2022 09:19:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47647 P = 0.007) and for those under 65 (19.0%; 95% CI, 8.1–28.6%) than for older people (6.6%; 95% CI, 1.9–11.1%; P = 0.030). There were no independent relationships between body mass index or alcohol consumption and pancreatic cancer. Conclusions: Strategies that reduce the uptake of smoking and encourage current smokers to quit could substantially reduce the future incidence of pancreatic cancer in Australia, particularly among men.]]> Tue 24 Jan 2023 14:51:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49325 Tue 14 Nov 2023 14:39:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45346 Thu 27 Oct 2022 10:29:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37419 Thu 27 Jan 2022 15:57:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35110 Pdifference < .001). The burden attributed to these factors was also higher for those born in Australia (28.7%) than elsewhere (16.8%, Pdifference = .047). We observed modification of the smoking-attributable burden by alcohol consumption and educational attainment, and modification of the obesity-attributable burden by age group and birthplace. Conclusions: We produced up-to-date estimates of the future CRC burden attributed to modifiable behaviors. We revealed novel differences between men and women, and other high–CRC burden subgroups that could potentially benefit most from programs that support behavioral change and early detection.]]> Thu 24 Mar 2022 11:32:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30583 Thu 17 Mar 2022 14:38:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30828 50% or PPV >65% for either cancer type and no combination of indicators increased both the sensitivity and PPV above that achieved using the hospital cancer diagnosis data. All specificities were close to 100%; 95% confidence intervals for sensitivity and PPV were generally +/−2%. Conclusions: In NSW, identifying new cases of colorectal and lung cancer from administrative health datasets, such as hospital records, is a feasible alternative when cancer registry data are not available. However, the strengths and limitations of the different data sources should be borne in mind.]]> Thu 13 Jan 2022 10:30:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35066 Thu 13 Jan 2022 10:28:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33626 Thu 03 Feb 2022 12:22:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10533 Sat 24 Mar 2018 08:13:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17372 Sat 24 Mar 2018 08:01:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19166 Sat 24 Mar 2018 07:52:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26835 Sat 24 Mar 2018 07:41:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27869 Sat 24 Mar 2018 07:41:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28048 Sat 24 Mar 2018 07:41:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29321 Sat 24 Mar 2018 07:34:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28430 Sat 24 Mar 2018 07:29:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22305 Sat 24 Mar 2018 07:11:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52851 30%. For each group, an age–period– cohort model or generalised linear model with cigarette smoking exposure as a covariate was selected based on the model fit statistics and validation using observed data. The smoking-attributable fraction (SAF) was calculated for each smoking-related cancer using Australian smoking prevalence data and published relative risks. Results: Despite the decreasing mortality rates projected for the period 2015–2019 to 2040–2044 for both men and women, the overall number of smoking-related cancer deaths is estimated to increase by 28.7% for men and 35.8% for women: from 138 707 (77 839 men and 60 868 women) in 2015–2019 to 182 819 (100 153 men and 82 666 women) in 2040–2044. Over the period 2020–2044, there will be 254 583 cancer deaths (173 943 men and 80 640 women) directly attributable to smoking, with lung, larynx, oesophagus and oral (comprising lip, oral cavity and pharynx) cancers having the largest SAFs. Interpretation: Cigarette smoking will cause over 250 000 cancer deaths in Australia from 2020 to 2044. Continued efforts in tobacco control remain a public health priority, even in countries where smoking prevalence has substantially declined.]]> Mon 30 Oct 2023 09:54:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51422 Mon 04 Sep 2023 14:57:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25323 64 years). Conclusions: Individual-level data are important for quantifying socioeconomic variation in CVD incidence, which is shown to be substantial among both those with and without prior CVD. Findings reinforce the opportunity for, and importance of, primary and secondary prevention and treatment in reducing socioeconomic variation in CVD and consequently the overall burden of CVD morbidity and mortality in Australia.]]> Fri 22 Apr 2022 10:26:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35870 Fri 21 Oct 2022 11:25:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40089 p<0.0001), smoking (p<0.0001) and unknown stage (p = 0.002). There was no evidence of differences by year of diagnosis or sex (both p>0.50). For 465 cases diagnosed 2014–2015, 29% had subsidised molecular testing for targeted therapy/immunotherapy and 4% had subsidised targeted therapies. Conclusions: Lung cancer healthcare costs are strongly associated with survival-related factors. Costs appeared stable over the period 2006–2013. This study provides a framework for evaluating the health/economic impact of introducing lung cancer screening and other interventions in Australia.]]> Fri 15 Jul 2022 10:04:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45747 Fri 04 Nov 2022 10:26:56 AEDT ]]>